CMPS
CMPS clinical trials: COMPASS Pathways plc
Every trial on ClinicalTrials.gov where COMPASS Pathways plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 9
- As lead sponsor
- 7
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CMPS on the catalyst calendar · CMPS registry changes
- Primary completion Nov 2028Sponsor estimatePhase 2/Phase 3NCT07570654Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderCOMPASS Pathways · PTSD - Post Traumatic Stress DisorderRecruitingCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 13, 2025ActualPhase 3NCT05711940Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDCOMPASS Pathways · Treatment Resistant DepressionActive, not recruitingCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2025ActualPhase 3NCT05624268Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDCOMPASS Pathways · Treatment Resistant DepressionCompletedCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2025Sponsor estimatePhase 2NCT05733546A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and...COMPASS Pathways · Major Depressive DisorderActive, not recruitingCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 12, 2024ActualPhase 2NCT05312151The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderCOMPASS Pathways · Post Traumatic Stress DisorderCompletedCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 18, 2024ActualPhase 2NCT05481736Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyCOMPASS Pathways · Anorexia NervosaCompletedCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 14, 2021ActualPhase 2NCT04739865The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionCOMPASS Pathways · Treatment Resistant DepressionCompletedCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2021ActualPhase 2NCT03775200The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionCOMPASS Pathways · Treatment Resistant DepressionCompletedCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2022ActualNo phase registeredNCT04519957Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)COMPASS Pathways · Treatment Resistant DepressionCompletedCMPSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2028Sponsor estimatePhase 3NCT06247839The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderSharmin Ghaznavi · Major Depressive DisorderRecruitingCMPSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 12, 2025ActualPhase 2NCT05220410The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationSheppard Pratt Health System · Treatment Resistant DepressionCompletedCMPSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2025Sponsor estimatePhase 2NCT04433858An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)Sheppard Pratt Health System · Treatment Resistant DepressionUnknown statusCMPSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2023ActualPhase 2NCT05381974The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDDMassachusetts General Hospital · Treatment-Resistant Major Depressive DisorderWithdrawnCMPSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2, 2022ActualPhase 2NCT04656301Safety and Efficacy of Psilocybin for Body Dysmorphic DisorderNew York State Psychiatric Institute · Body Dysmorphic DisordersCompletedCMPSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2023Sponsor estimatePhase 2NCT04433845The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.Sheppard Pratt Health System · Treatment Resistant DepressionUnknown statusCMPSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 10, 2022ActualPhase 2NCT04661514Evaluation of Psilocybin in Anorexia Nervosa: Safety and EfficacyUniversity of California, San Diego · Anorexia NervosaCompletedCMPSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner